13
Jun 2026
New DNA test improves diagnosis of rare genetic disorders
A new test provides a much more complete picture of DNA than current standard diagnostics and leads to a diagnosis more often.
Stay Informed!
13
Jun 2026
Phase 3 study of in vivo CRISPR therapy for hereditary angioedema successfully completed
Researchers from Amsterdam UMC, in collaboration with other hospitals, have successfully completed the first-ever Phase 3 study of an in vivo CRISPR therapy.
13
Jun 2026
Grandparents can help counter growing children's mental health challenges
As more than 40% of American teenagers report persistent feelings of sadness or hopelessness, a leading child psychologist says grandparents and extended family have a vital role to play.
13
Jun 2026
Solent student masters the art of fake wounds to create life-saving simulations for the military and NHS
A Southampton Solent University student is set to graduate with two jobs already secured, one with the Ambulance Service and one delivering trauma simulation training for the British military.
12
Jun 2026
Noninvasive sequencing expands prenatal genetic screening capabilities
While non-invasive prenatal testing (NIPT) has revolutionised prenatal diagnostics by allowing the detection of a number of genetic problems in a fetus, it is currently limited and thus misses many genetic causes of abnormalities.
12
Jun 2026
Trauma-related conditions drive deaths in women with HIV
Women with HIV most often die from preventable, trauma-related conditions like substance use and mental illness - not the virus itself. Yet, these leading causes are largely missing from official death records, according to new research by UC San Francisco.
12
Jun 2026
Researchers identify vulnerabilities shared by surviving cancer cells
Cancer drugs can shrink fast-growing tumors. But sometimes a few tumor cells survive. These "persister" cells seed new tumors, forcing cancer patients into arduous cycles of testing and treatment.
12
Jun 2026
FDA approves new adjuvant treatment option for ccRCC patients with recurrence risk
The U.S. Food and Drug Administration (FDA) has approved pembrolizumab, an immunotherapy, plus belzutifan, a HIF-2α inhibitor, as adjuvant treatment for adult patients with renal cell carcinoma with a clear cell component (ccRCC) at intermediate-high or high risk of recurrence following nephrectomy, with or without resection of metastatic lesions.
12
Jun 2026
Renowned physician‑scientist to lead Houston Methodist's cell and gene therapy research
Malcolm Brenner, an internationally recognized physician‑scientist renowned for his leadership in cell and gene therapy, has been tapped to lead the newly formed Houston Methodist Center for Cell and Gene Therapy.
12
Jun 2026
Major NIH grant helps establish the Oklahoma Center of ImmunoEngineering
The University of Oklahoma has received an $11.5 million award from the National Institutes of Health to establish the Oklahoma Center of ImmunoEngineering, a new research center designed to accelerate the study and treatment of diseases rooted in the immune system.
